Сергей Пузанов – Multiple Sclerosis. Everything you need to know (страница 19)
Let's look at the financial math behind Rebif:
The drug rolled off the line in two distinct strengths—22 mcg and 44 mcg. Bizarrely, both tracks required three injections a week. The 22 mcg was the baseline, but patients whose bodies tolerated the side effects were urged to double the dose to unlock "maximum efficacy." How this double-up shifted the biological baseline was never clearly mapped out, but a single 22 mcg shot in the 2010s cost about $300, while the 44 mcg version retailed for $400. It looks a lot like the pricing strategy for a small versus a large cappuccino, doesn't it?
At launch, a year of Rebif therapy was priced roughly 1.5 times higher than both Betaseron and Avonex.
The clinical trials claimed Rebif cut relapses by 29–32% and slowed disability by 23–31%. Remember, Avonex claimed an 18% relapse drop and a 37% disability slowdown. Don't ask me how this mathematical contradiction is biologically possible—nobody knows.
By 2003, Rebif sales shattered the $800 million mark, accounting for a massive 44.1% of Serono’s total corporate revenue.
In 2013, global Rebif sales soared to roughly $2.5 billion, locking it in as the third best-selling multiple sclerosis drug on Earth.
Cumulatively, Rebif has drained global healthcare budgets to the tune of $24 billion.
Do you think the market hit equilibrium there? Not even close. This entire pharmaceutical crossfire unfolded right at the dawn of mass MS diagnostics via MRI. Rebif unlocked its US registration in 2002, and over the subsequent three years, the estimated number of diagnosed patients in the United States exploded from 250,000 to 400,000. This spike was driven entirely by the systemic rollout of tomographs and the arrival of the 2001 McDonald criteria. Pharmaceutical companies launched a highly aggressive medical campaign branded as the "Window of Opportunity." Sales reps bombarded neurologists with the message that every single day a patient spends without therapy results in the irreversible burning away of their brain tissue. Doctors were urged to abandon years of clinical observation and slap on a diagnosis at the absolute first hint of trouble.
Pegylated Interferons Beta-1a
Pegylation is a biochemical process where an interferon molecule is structurally bound to a chain of polyethylene glycol (PEG). This modification cloaks the interferon, making it incredibly stable and resilient against the body’s clearing enzymes. It drastically extends the drug's half-life, which, in plain terms, allows the patient to slash the frequency of their injections. When Rebif's trial data established a new benchmark for corporate performance, everyone else in the market who wanted to secure a piece of the relapsing-remitting MS gold mine had to cook up something radically fresh. Playing around with minor tweaks to dosages, injection schedules, relapse rates, and EDSS charts could only carry a brand so far—eventually, even the FDA’s patience would bottom out.
By the late 1990s, Rebif had cannibalized a massive chunk of Avonex’s market share, and the board of directors at Biogen was feeling the heat. Things looked exceptionally bleak in Europe, where Rebif had bypassed legal blockades and registered instantly—the US market had been insulated until 2002 solely by Biogen's scorched-earth courtroom tactics. Rebif's trials proved it was more effective, which made perfect logical sense given the three-times-a-week injection schedule, and Avonex’s long-term market position looked dead in the water. But the executives at Biogen understood the mechanics of the pharmaceutical industry inside out. They launched a long-term counter-offensive years before the trap snapped shut.
The engineering of an interferon with an extended half-life kicked off around 2003–2004, serving as a direct corporate answer to Serono's offensive. There was zero running room left within the boundaries of existing interferon parameters, so to keep the cash flowing, they had to introduce a brand-new variable to the board. They needed the illusion of an absolute breakthrough—a scientific miracle. They needed a product that doctors could pitch to scared patients as a revolutionary new weapon. It was an incredibly complex marketing puzzle, but when you are chasing billions of dollars, nothing is impossible: in the summer of 2014, a drug called Plegridy hit the shelves simultaneously in Europe and the United States.
The trial design for Plegridy mirrored the industry's gold standards: a basic saline solution as a placebo, completely unblinded conditions driven by violent side effects, and cleanly positive yet utterly unremarkable medical results. However, the study—code-named ADVANCE—featured one fascinating structural twist. During the first phase, they contrasted Plegridy against the placebo, but in the second phase, they compared Plegridy injected once every 2 weeks against Plegridy injected once every 4 weeks. Biogen clearly wanted to lock down and monopolize the optimal injection schedule for long-acting interferons. Crucially, they never ran a direct comparison between a once-a-week and a once-every-two-weeks track. If a patient wanted a weekly shot, Biogen already had a product for that: Avonex.
Let's look at the facts behind Plegridy:
Injected once every 2 weeks, Plegridy lowered the annual relapse rate by 36%.
Injected once every 4 weeks, it reduced relapses by 28%. By publishing data on less frequent dosing, Biogen didn't just give patients an illusion of choice; they mathematically "proved" to them that taking the shot kept the disease down, while backing off increased the risk of flare-ups.
Plegridy cut the risk of confirmed disability progression by 38%.
A massive 71% of patients on the bi-weekly Plegridy track went the entire year of the study without a single registered relapse.
By the way, the fact that Plegridy could be taken so infrequently wasn't just a miracle of pegylation—it was also fueled by a massive increase in the active compound. The titration schedule makes this obvious. The first shot is 63 mcg in an orange syringe; the second is 94 mcg in a blue one; and then you transition to a standard 125 mcg dose in gray syringes. This means the maintenance dose is more than four times larger than Avonex—despite the pegylated shield and the extended half-life. Naturally, this question was repeatedly raised at medical congresses. Biogen’s official corporate answer was that a massive volume of the active compound was mandatory to stretch the therapeutic plateau for a flawless 14 days, matching the efficacy of high-frequency shots. Remarkably, cranking up the chemical volume had almost zero impact on the severity of the flu-like side effects.
This brings us right back to MS diagnostics via MRI. Throughout the 2000s and 2010s, the official multiple sclerosis patient counts in the United States were swelling like rising dough—epidemiological surveys show the numbers jumping from 400,000 in 2003 to a massive 900,000 by 2019. Under the influence of loose diagnostic criteria and ubiquitous MRI scanners, the average "profile" of an MS patient shifted completely. The newer interferons looked incomparably more effective on paper—not because the molecules had undergone a biological evolution, but because the trial pools were increasingly packed with early-stage, asymptomatic, and highly ambiguous cases. In 1998, during the Rebif trials, the placebo group averaged 1.28 relapses a year. By 2014, in the Plegridy trials, the placebo group’s relapse rate plummeted to a measly 0.40. The old-school interferons would have loved to test their steel against this fresh, mild pool of patients, but unfortunately, that's not how the market works.
It's also worth noting that the Plegridy trials leaned heavily on detailed MRI metrics. By the 2010s, high-resolution tomographs sat in every local clinic, and ignoring this data stream was impossible. While older interferons made vague references to "reducing spot counts," Plegridy arrived with ironclad data metrics: injecting the drug once every 2 weeks drove a 67% reduction in new or expanding T2 lesions and slashed contrast-accumulating hotspots by a staggering 86%. On paper, Plegridy practically guaranteed MS patients a flawless, fully functional life straight into old age—at least, as long as you evaluated success purely by looking at an MRI screen.
In total, over the span of 20 years, the market engineered three generations of interferon (beta-1b, beta-1a, and pegylated beta-1a) and deployed two delivery tracks (intramuscular and subcutaneous). An attentive reader will notice that we haven't said a word about an intramuscular track for pegylated interferons—don't worry, the strategists at Biogen spotted that running room too. In February 2021, they secured FDA approval for Plegridy IM (Intramuscular). This new track cut injection-site skin necrosis from 32.1% down to 14.4%. Deep muscle tissue is packed with blood vessels, allowing the massive protein molecule to wash out into the system before it can cause the skin overlaying it to rot away. Most importantly, this fresh delivery track allowed Biogen to secure a brand-new patent, extending their corporate monopoly over pegylated interferons for years.